Scientists said on Monday they had used cloning technology to make embryonic stem cells that carry a diabetic woman’s genes, and turned them into insulin-producing beta cells that may one day cure her disease.
The team reported clearing an important hurdle in the quest to make “personalised stem cells” for use in disease therapy, but a bioethicist said the breakthrough also highlighted the need for better regulation of lab-grown embryos.
“We are now one step closer to being able to treat diabetic patients with their own insulin-producing cells,” said Dieter Egli of the New York Stem Cell Foundation (NYSCF), who led
Regenerative medicine took a step forward on Monday with the announcement of the creation of the first disease-specific line of embryonic stem cells made with a patient’s own DNA (…)
“This is a really important step forward in our quest to develop healthy, patient-specific stem cells that can be used to replace cells that are diseased or dead,” said Susan Solomon, chief executive officer of NYSCF, which she co-founded in 2005 partly to search for a cure for her son’s diabetes.
Stem cells could one day be used to treat not only diabetes but also other diseases, such as Parkinson’s and
Image by engineroomblog via Flickr
Using skin cells from people with type 1 diabetes, researchers were able to produce cells that made insulin in response to changing blood sugar levels, though not as efficiently as normal insulin-producing cells do. (…) “This is a big deal,” said Susan Solomon, CEO of the New York Stem Cell Foundation, which provided some of the funding for the study. “Tackling the basic biology of type 1 diabetes, which is a very complex disease, is a critical step. With these cells, we can see in a dish what’s happening to the immune system, and if
Five years after Harvard researchers first received institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), a young scientist who worked in the Harvard program as a postdoctoral fellow has succeeded in using the process — known as therapeutic cloning — to produce a stem cell line containing the genes of a patient with type 1 diabetes.
In papers in Nature, Nature Communications, and Cell Stem Cell, that scientist, who is now at the independent New York Stem Cell Foundation (NYSCF) laboratory, and Harvard researchers, report on the SCNT advance. In addition, they report on an experiment explaining why other attempts at
The capacity to reprogram adult patient cells into pluripotent, embryonic-like, stem cells by nuclear transfer has been reported as a breakthrough by scientists from the US and the Hebrew University of Jerusalem.
The work, described in the journal Nature, was accomplished by researchers from the New York Stem Cell Foundation Research Institute and Columbia University and by Nissim Benvenisty, the Herbert Cohn professor of Cancer Research and director of the Stem Cell Unit at the Institute of Life Sciences at the Hebrew University of Jerusalem, and his graduate student Ido Sagi. The latter assisted in the characterization of the pluripotent